Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 31 May 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; VCAR 33 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 13 May 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2029.
- 13 May 2024 Status changed from active, no longer recruiting to recruiting.
- 12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition.